Tag Archives: Adcetris: Pfizer drug succeeds in late-stage blood cancer trial

Pfizer said on Tuesday a combination treatment using its drug, Adcetris, met the main goal of a late-stage study of extending survival in patients with a type of blood cancer. The safety and tolerability of ADCETRIS in the ECHELON-3 trial were consistent with what has been previously presented for patients with relapsed/refractory DLBCL treated with ADCETRIS in clinical trials. Full …

Read More »